% | $
Quotes you view appear here for quick access.

FRX Message Board

  • spaceout747 spaceout747 Jan 14, 2013 1:28 PM Flag

    Carl Icahn Large Position FRX By Federico Zaldua - January 14, 2013

    Icahn’s third position is Forest Labs (NYSE: FRX). I think he is attracted by the fact that Forest’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. Of course, Icahn wants to add his own directors to Forest´s management team in order to increase shareholder value. Forest has developed one of the most promising product pipelines in the industry, receiving seven product approvals in seven different indications in just the past five years that includes the recently FDA approval for aclidinium. I think that Icahn recognizes that Forest has built a track record of new product development that compares favorably to its peers, as well as many of the largest global pharma companies,